Now Available: Spotlight on DELFI Diagnostics CEO Susan Tousi. Click here to read.
Diagnostic tests are vital, but the current system can be challenging. Blood draw sites are often inconvenient, and patients can wait days for results. In addition, people testing for sexually transmitted diseases (STDs), and other potentially sensitive conditions, may opt-out over privacy concerns. Sherlock Biosciences is working to address these issues by changing how people access diagnostics.
Walking Fish Therapeutics was named after the Axolotl, a small amphibian that can regenerate lost limbs and even a damaged heart. The company’s co-founder, chairman and CEO, Rusty Williams, MD, PhD, has long marveled at this capacity and draws on it for inspiration.
Proteomics firm Alamar Biosciences is preparing its NULISA (NUcleic acid-Linked Immuno-Sandwich Assay) platform for an early-access release later this year and a broad commercial launch in 2024. The NULISA system is based on the proximity ligation assay (PLA) originally commercialized by Olink Bioscience, the forerunner of Olink. PLA uses pairs of antibodies attached to unique DNA sequences to...
RedShiftBio has created a platform that combines microfluidic modulation spectroscopy (MMS) and quantum cascade lasers to generate precise, ultra-sensitive molecular structure measurements. “We are helping our customers see things they simply could not see before because it was too challenging or they didn't have the sensitivity or resolution,” said CEO Julien Bradley. “This technology opens ...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
